TP53 and acute myeloid leukemia: In addition, single-cell sequencing of peripheral blood mononuclear cells (PBMCs) in a non-acute promyelocytic leukemia (APL) AML patient harboring a type 1 mutp53 after ATO monotherapy revealed upregulation of the classical p53 target gene and a significant reduction in minimal residual disease (MRD) in blood samples [79].